Indefinite Delivery Contract 75D30125D20402
Award Date
12/31/24
Last Date to Order
2/28/26
Federal Agency
CDC Pittsburgh
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Indefinite Delivery Contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC) to the pharmaceutical company Glaxosmithkline, LLC to provide pediatric influenza vaccines for the 2024-2025 timeframe. The contract has a ceiling value of $182,592,000 and a period of performance through February 28, 2025. Glaxosmithkline, a foreign-owned for-profit organization, has extensive experience as a prime contractor providing a range of pharmaceutical products and services to...
The federal contract IDV award to Glaxosmithkline, LLC is for the supply of pediatric influenza vaccines to the Centers for Disease Control and Prevention (CDC) for distribution to immunization programs under the Section 317(j) Public Health Service Act and Vaccines for Children program. The single-award contract has a ceiling value of $161,025,000 and a period of performance from December 31, 2020 to February 28, 2022. The contract was issued in response to a CDC solicitation for a minimum...
This multiple award IDV was issued by the Department of Health and Human Services Centers for Disease Control and Prevention Pittsburgh to procure pediatric flu vaccines for the 2023-2024 flu season. Glaxosmithkline, LLC was awarded the IDV as prime contractor. The IDV does not include any set-asides and has a potential value of $174.9 million. Orders may be placed through February 2024 to deliver pediatric flu vaccines in support of the CDC's efforts to increase vaccination rates among...
The federal contract IDV award is a $13,916,000 Indefinite Delivery Contract issued by the Centers for Disease Control and Prevention (CDC) to GlaxoSmithKline, LLC to provide adult influenza vaccines for the 2025-2026 season. The contract has a period of performance through February 28, 2026. GlaxoSmithKline, a pharmaceutical company that supplies vaccines and other products to federal agencies, will deliver the seasonal flu vaccines under this multiple award IDV contract. The contract vehicle...
The federal contract IDV awarded to Glaxosmithkline, LLC is a $83,834,950 Indefinite Delivery Contract to provide a range of adult vaccines to the Centers for Disease Control and Prevention (CDC) for a period of performance through June 30, 2019. The single-award contract was issued without any set-aside designation. The contract aims to procure various pharmaceutical products and immunization services to support public health initiatives, including influenza vaccines, hepatitis vaccines,...
The Centers for Disease Control and Prevention (CDC) awarded a single award Indefinite Delivery Contract to Glaxosmithkline, LLC, a pharmaceutical company, to procure pediatric influenza vaccines for the 2022-2023 season. The contract has a potential value of $168,590,000 and a period of performance from the date of award through February 28, 2023. The original solicitation sought between 100 doses and 50 million doses of pediatric influenza vaccine to be delivered to CDC distribution centers in...
The federal contract IDV award SPE2DP18D0006 is a single-award indefinite delivery contract issued by the U.S. Department of Defense (DoD) Medical Supply Chain to the pharmaceutical company Glaxosmithkline, LLC. The contract, valued at a ceiling of $27,848,725.95, enables the DoD to order influenza virus vaccines and other pharmaceutical products from Glaxosmithkline, a foreign-owned for-profit organization, over the term of the agreement. Task orders issued under the IDV provide for the firm...
The federal contract IDV is a multiple-award Federal Supply Schedule contract with the Department of Veterans Affairs (VA) for the procurement of pharmaceutical products, medical supplies, and vaccines. The contract has a total ceiling value of $3.9 billion and a period of performance through July 31, 2027. The prime contractor is Glaxosmithkline, LLC, a foreign-owned, for-profit pharmaceutical company that provides a range of medical products to various federal agencies. Under this IDV,...
This federal contract IDV is awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to procure a range of pediatric vaccines for the agency's Immunization Awardees program and Vaccines for Children program. The 5-year, $1.3 billion multiple award contract enables the CDC to purchase between 100 doses and 13 million doses of 27 different pediatric vaccines from the prime contractor, Glaxosmithkline, LLC. The vaccines must...
The federal contract IDV award is an Indefinite Delivery Contract held by Pfizer Inc. for the Centers for Disease Control and Prevention (CDC) Vaccines for Children (VFC) program. The contract has a ceiling value of $2,007,801,000.00 and a period of performance from April 1, 2025, through March 30, 2026. Under this IDV, Pfizer will provide a range of standard commercial pediatric vaccines to support immunization efforts for eligible children, including those who are Medicaid-eligible, uninsured,...